Galderma was founded in 1981 as a joint venture between Nestlé and L’Oreal with the goal of establishing a pharmaceutical company exclusively focused on the field of dermatology. Today the company has over 3000 employees in 31 affiliates around the world with three manufacturing sites and the largest R&D facility dedicated exclusively to dermatology.
Prescription Products
|
Prescription dermatology represents the core of Galderma’s business. Galderma is seeking innovative new compounds to develop first-in-class or best-in-class products that provide therapeutic solutions to a wide variety of dermatological conditions.
Disease targets include:
- Acne,
- Psoriasis and steroid-responsive dermatoses,
- Rosacea,
- Onychomycosis,
- Pigmentary disorders,
- Skin cancer,
- Medical solutions for skin senescence.
Our criteria for prescription dermatology development programs include:
- Topical or systemic,
- Small molecule or biological,
- Safety profiled,
- Known mechanism of action,
- Comparative in vitro and in vivo pharmacology data versus reference products,
- Proof of concept in humans.
We are also seeking to acquire or in-license programs or technologies to support and complement our internal research efforts, such as:
- Compound libraries,
- Compound library management (purity, concentration, storage, composition, biased libraries),
- Pathology-oriented cellular assays and in vivo models,
- Validated targets (e.g. GCPR’s, ION channels, enzymes, nuclear receptors).
|
Corrective & Aesthetic Dermatology
|
Galderma’s global sales force coverage, its leading image among healthcare providers and significant commitment to research and development have positioned the company as a leader in dermatology. Expanding this commitment to include the corrective and aesthetic dermatology segment is a natural evolution of the Company’s strategy to provide innovative medical solutions that meet the needs of dermatology patients and physicians.
Several years ago Galderma evolved its traditional pharmaceutical business model to incorporate the field of corrective and aesthetic dermatology. In 2001, the Company entered into the emerging field of photodynamic therapy, an initiative that progressively accelerated with increased activity and investment, culminating in 2009 when the Company purchased the assets and rights to Metvix, worldwide. In 2008, Galderma began promoting and selling its proprietary botulinum toxin product in South America. This activity was expanded with the approval and launch of Azzalure in Europe in 2009. The Company has active partnerships to expand its product offering to include a range of hyaluronic acid-based dermal filler products and a topical anesthetic product. In addition, the Company has a number of internal programs focused on medical solutions for skin senescence.
Beyond skin senescence, Galderma is developing medical solutions for corrective and aesthetic applications in most of the other therapeutic areas that the Company serves, including acne, rosacea, psoriasis and steroid-responsive dermatoses, pigmentary disorders, onychomycosis and skin cancer. While the Company commercializes pharmaceutical products for all of these therapeutic areas, Galderma is also focused on developing medical procedures that help healthcare providers optimize patient outcomes.
We are seeking to acquire or in-license products or technology in the following areas:
- Dermal fillers,
- Muscle relaxants,
- Energy-based devices,
- Other medical devices,
- Prescription companion products associated with procedures,
- Pre and post aesthetic procedure OTC skin care products.
|
Galderma was founded in 1981 as a joint venture between Nestlé and L’Oreal with the goal of establishing a pharmaceutical company exclusively focused on the field of dermatology. Today the company has over 3000 employees in 31 affiliates around the world with three manufacturing sites and the largest R&D facility dedicated exclusively to dermatology.
Prescription Products
|
Prescription dermatology represents the core of Galderma’s business. Galderma is seeking innovative new compounds to develop first-in-class or best-in-class products that provide therapeutic solutions to a wide variety of dermatological conditions.
Disease targets include:
- Acne,
- Psoriasis and steroid-responsive dermatoses,
- Rosacea,
- Onychomycosis,
- Pigmentary disorders,
- Skin cancer,
- Medical solutions for skin senescence.
Our criteria for prescription dermatology development programs include:
- Topical or systemic,
- Small molecule or biological,
- Safety profiled,
- Known mechanism of action,
- Comparative in vitro and in vivo pharmacology data versus reference products,
- Proof of concept in humans.
We are also seeking to acquire or in-license programs or technologies to support and complement our internal research efforts, such as:
- Compound libraries,
- Compound library management (purity, concentration, storage, composition, biased libraries),
- Pathology-oriented cellular assays and in vivo models,
- Validated targets (e.g. GCPR’s, ION channels, enzymes, nuclear receptors).
|
Corrective & Aesthetic Dermatology
|
Galderma’s global sales force coverage, its leading image among healthcare providers and significant commitment to research and development have positioned the company as a leader in dermatology. Expanding this commitment to include the corrective and aesthetic dermatology segment is a natural evolution of the Company’s strategy to provide innovative medical solutions that meet the needs of dermatology patients and physicians.
Several years ago Galderma evolved its traditional pharmaceutical business model to incorporate the field of corrective and aesthetic dermatology. In 2001, the Company entered into the emerging field of photodynamic therapy, an initiative that progressively accelerated with increased activity and investment, culminating in 2009 when the Company purchased the assets and rights to Metvix, worldwide. In 2008, Galderma began promoting and selling its proprietary botulinum toxin product in South America. This activity was expanded with the approval and launch of Azzalure in Europe in 2009. The Company has active partnerships to expand its product offering to include a range of hyaluronic acid-based dermal filler products and a topical anesthetic product. In addition, the Company has a number of internal programs focused on medical solutions for skin senescence.
Beyond skin senescence, Galderma is developing medical solutions for corrective and aesthetic applications in most of the other therapeutic areas that the Company serves, including acne, rosacea, psoriasis and steroid-responsive dermatoses, pigmentary disorders, onychomycosis and skin cancer. While the Company commercializes pharmaceutical products for all of these therapeutic areas, Galderma is also focused on developing medical procedures that help healthcare providers optimize patient outcomes.
We are seeking to acquire or in-license products or technology in the following areas:
- Dermal fillers,
- Muscle relaxants,
- Energy-based devices,
- Other medical devices,
- Prescription companion products associated with procedures,
- Pre and post aesthetic procedure OTC skin care products.
|
|